Spirotriazoline oxindoles: A novel chemical scaffold with in vitro anticancer properties
作者:Carlos J.A. Ribeiro、Rute C. Nunes、Joana D. Amaral、Lídia M. Gonçalves、Cecília M.P. Rodrigues、Rui Moreira、Maria M.M. Santos
DOI:10.1016/j.ejmech.2017.09.037
日期:2017.11
design and synthesis of a library of twenty-six spirotriazoline oxindoles and their in vitro evaluation as potential anticancer agents is reported. The antiproliferative activity of the synthesized compounds was assessed against four different cancer cell lines (HCT-116 p53 (+/+), HCT-116 p53 (−/−), MCF-7, and MDA-MB-231). Four spirotriazoline oxindoles showed selectivity against the four cancer cell
报道了二十六个螺三唑啉恶唑的文库的设计和合成,以及作为潜在抗癌药的体外评价。评估了合成化合物对四种不同癌细胞系(HCT-116 p53 (+ / +),HCT-116 p53 (-/-),MCF-7和MDA-MB-231)。相对于非癌症衍生的HEK 293T细胞系,四个螺三唑啉羟吲哚显示出对四种癌细胞系的选择性。为了表征涉及复合抗肿瘤活性的分子机制,选择了两个螺三唑啉恶吲哚用于进一步研究。在HCT-116细胞中,这两种化合物均能够诱导细胞凋亡和细胞周期停滞在G0 / G1期并上调p53稳态水平,同时降低其主要抑制剂MDM2。重要的是,在非恶性CCD-18Co人结肠成纤维细胞中,螺三唑啉恶唑诱导的细胞毒性作用在癌细胞中发生,而不会引起细胞死亡。此外,四个螺三唑啉恶唑类化合物对具有IC 50的三阴性乳腺癌细胞系MDA-MB-231具有选择性值为3.5–6.7μM。这些结果突出了螺三唑啉恶唑类的